Literature DB >> 769820

The effect of cytotoxic drugs on neutrophil phagocytosis in vitro and in patients with acute myelogenous leukaemia.

J E Davies, J A Whittaker, M Khurshid.   

Abstract

The in vitro effects of a range of concentrations of cyclophosphamide, doxorubicin, actinomycin D, cytarabine and methotrexate on neutrophil phagocytosis of C. albicans was studied. The reduction in phagocytic index (PI) was inversely proportional to the dilution of the drug and there was some inhibition of phagocytosis at all dilutions of all drugs. In patients with acute myelogenous leukaemia (AML), in vivo experiments showed that remission chemotherapy of doxorubicin or daunorubicin together with cytosine arabinoside increasingly inhibited phagocytosis over the period studied. The importance of these findings in the chemotherapy of malignant disease and the possible mode of action of cytotoxic drugs are discussed.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 769820     DOI: 10.1111/j.1365-2141.1976.tb01871.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  Assessment of neutrophil function in canine cancer patients undergoing chemotherapy and correlation with neutrophil numbers.

Authors:  Arefeh Ravanbakhsh; Khawaja Ashfaque Ahmed; Valerie MacDonald-Dickinson; Nicole J Fernandez; Melissa D Meachem; Ryan M Dickinson
Journal:  Can J Vet Res       Date:  2021-04       Impact factor: 1.310

2.  Assessment of host defence against infection during chemotherapy of Hodgkin's disease.

Authors:  I Addison; J Babbage; M Gandossini; R Souhami
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

3.  Effects of high-dose methotrexate on rat alveolar and inflammatory macrophage populations.

Authors:  J M Zeller; C M Buys; P W Gudewicz
Journal:  Inflammation       Date:  1984-09       Impact factor: 4.092

4.  Effect of therapeutic concentrations of anthracyclines on monocyte phagocytosis of yeast cells.

Authors:  L Athlin; L Domellöf; B Norberg
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.